Your search for major depressive disorder returned 13 results

In this review, authors focused on the psychiatric issues that often accompany migraine and the effects of botulinum toxin A on migraine.

Researchers set out to evaluate whether propranolol efficacy is greater in people with comorbid migraine compared with those without migraine.

Study investigators sought to determine if galcanezumab would reduce not only the frequency of migraine days but also the disabling nonpain symptoms of episodic and chronic migraine.

The objective of this post hoc analysis is to better assess the benefits of fremanezumab in patients who responded to treatment during 2 phase 3 HALO clinical trials.

Dr Amit Akirov examines the evidence suggesting associations between migraine and major depressive disorder (MDD).

A pooled analysis evaluated reductions in migraine and headache days among patients with chronic migraine and comorbid depression in 2 placebo-controlled, phase 3 trials of fremanezumab.

Various migraine subgroups based on comorbidities can predict the risk for the progression of episodic migraine to chronic migraine.

Researchers found evidence for a divergent association between lifetime MDD and the prevalence and severity of symptoms in patients with migraine.

The presence of psychiatric disorders in patients with idiopathic intracranial hypertension is associated with poor treatment outcomes.

Migraine with active headache may predict other painful physical symptoms in patients with major depressive disorder.

People with migraines and comorbid mood disorders often need treatments that address both conditions, as well as management of sleep, stress, and lifestyle issues.

Migraine was more significantly associated with pain or muscle soreness than anxiety disorders in patients with depression.

New findings suggest shared genetic etiology vs causal relationship in comorbid migraine and depression.